Background: Although sorafenib-regorafenib sequential therapy improves the prognosis of patients with hepatocellular carcinoma (HCC), many patients abandon sequential therapy due to worsening hepatic reserve function. Thus, it is important to clarify which patients can be treated using regorafenib. The albumin-bilirubin score is a good biomarker for hepatic reserve function. The aim of this study was to determine whether patient albumin-bilirubin scores at the start of sorafenib treatment could be used to identify candidates for subsequent regorafenib therapy. Methods: This is a retrospective cohort study. From 2009 to 2017, 267 hepatocellular carcinoma patients treated with sorafenib were enrolled. After sorafenib therapy, 138 progressive disease patients were analyzed. The patients were divided in two groups: (i) regorafenib candidate group (Child-Pugh class A, Eastern Cooperative Oncology Group Performance Status ≤1, and maintained sorafenib tolerance); and (ii) regorafenib non-candidate group. The primary endpoint was the albumin-bilirubin score. We assessed retrospectively whether albumin-bilirubin scores were useful for predicting regorafenib treatment regimen candidacy. Results: For the 138 analyzed patients, the median overall survival duration was 15.6 months in the regorafenib candidate group and 6.8 months in the regorafenib non-candidate group (P < 0.01). Using univariate analysis, etiology, aspartate aminotransferase ≥40 IU/L, prothrombin time ≥85% and albumin-bilirubin score <−2.53 at the start of sorafenib treatment were identified as predictors. Using multivariate analysis, albumin-bilirubin score <−2.53 was the only significant predictor. Conclusions: Based on the multivariate analysis results, albumin-bilirubin score at the start of sorafenib therapy is a useful marker for identifying candidate patients for starting regorafenib therapy.
Introduction
In recent decades, sorafenib has been the only effective drug for treating advanced hepatocellular carcinoma (HCC). In both the SHARP trial and the Asia-Pacific trial, the median overall survival duration of the sorafenib group was significantly improved (1, 2) . The SHARP trial was a multicenter phase 3 double-blind placebocontrolled trial mainly conducted in Europe and the USA, whereas the Asia-Pacific trial was a phase 3 randomized double-blind placebo-controlled trial conducted on an Asian patient population. Though sorafenib has been found to be effective for overall survival, the disease control rate has been poor. Most patients receiving sorafenib therapy deteriorate before long. Thus, second-line chemotherapy has been required, but it has not been developed for a long time.
Recently, regorafenib has been employed as second-line therapy for advanced HCC after sorafenib failure. In the RESORCE trial, patients who have experienced disease progression during sorafenib treatment were treated with regorafenib. In this trial, the overall survival rate in the regorafenib group was about 2.8 months longer than in the placebo group {hazard ratio 0.63 [95% confidence interval (CI) 0.50-0.79]} (3).
Regorafenib is a multi-kinase inhibitor that inhibits key proteins involved in proliferation, tumor angiogenesis and metastasis (4, 5) . Regorafenib also appears to be a more potent inhibitor of oncogenic kinases such as RET, RAF-1 and KIT than sorafenib (6, 7) . Regorafenib has been approved for advanced colon cancer and gastrointestinal stromal tumor therapeutics (8, 9) and has demonstrated acceptable tolerability and antitumor activity for advanced HCC (10) .
The RESORCE trial established that patients continuing sorafenib at 400 mg or greater doses without intolerable adverse events for at least 20 of the last 28 days of treatment could be treated using regorafenib. Moreover, maintaining Child-Pugh A and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) values ≤1 was required. Thus, it is important to determine whether regorafenib can be used at the time of sorafenib failure. It has been reported that only about 30% of patients are eligible for regorafenib treatment (11) .
We have previously reported that the (albumin-bilirubin) ALBI score is a better biomarker of hepatic reserve function than the Child-Pugh score (12) . Therefore, we conducted a retroactive multicenter study examining the characteristics of HCC patients treated with sorafenib to assess whether ALBI score at the start of sorafenib treatment was a useful marker of eligibility for regorafenib therapy.
Methods
From 2009 to 2017, 267 patients with advanced HCC were treated with sorafenib as the first-line therapy. The primary endpoint was ALBI score at the start of sorafenib treatment. In this retrospective study, the inclusion criteria were defined as follows: (i) Child-Pugh A or B; (ii) ECOG-PS ≤ 2; (iii) platelet count ≥60 000/mm 3 ; (iv) alanine aminotransferase (ALT) ≤5× upper limit of normal (ULN); (v) aspartate aminotransferase (AST) ≤5× ULN and (vi) adequate cardiac, pulmonary and renal function. Patients with other diseases such as infections, cancers other than HCC, and immunodeficiency, which can affect sorafenib treatment, were excluded. After sorafenib therapy, only progressive disease patients were enrolled. Overall, 138 of 267 patients met the criteria for enrollment (Fig. 1) . These enrolled patients were divided into two groups (regorafenib candidate or regorafenib non-candidate groups). Inclusion in the regorafenib candidate group was determined using the RESORCE trial criteria: patients with Child-Pugh class A and ECOG-PS values ≤1 who maintained sorafenib tolerance (≥400 mg/day for ≥20 of the last 28 days of treatment). The duration of overall survival was assessed from sorafenib treatment start date. Adverse effects of sorafenib were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Sorafenib doses were modified in the event of clinical toxicity. For dermatological toxicities (grade 2-3 adverse events), sorafenib was discontinued until resolution to grade 0-1. Sorafenib doses were reduced to 400 mg/day or 400 mg/every 2 days at the first appearance of toxicity. Sorafenib doses were decreased with grade 3 or 4 hematologic toxicities. With grade 4 hematologic toxicities, administration was delayed until resolution to grade 2. With grade 3 non-hematologic and skin toxicities, administration was delayed until resolution to grade 0-2 and the sorafenib dosages were changed. With grade 4 toxicities, sorafenib therapy was discontinued. Therapeutic effects were evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1). ALBI scores were calculated using serum albumin and bilirubin values [ALBI score
This study was approved by the Institutional Review Board and was performed in accordance with the ethical principles of the Declaration of Helsinki.
Statistical analysis
Statistical analyses were performed using Easy R (EZR) version 1.36 (https://www.r-project.org) (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for the R statistical Computing Environment (R Foundation, Vienna, Austria). Quantitative variables following a normal deviation are expressed as means with standard deviations. Quantitative variables not following a normal deviation and qualitative variables are expressed as medians with interquartile ranges (25th and 75th percentiles).
Two groups were compared using Fisher's exact test and χ 2 test.
Categories identified as significant using univariate analysis (P < 0.05) were further subjected to multivariate analysis by binary logistic regression. For multivariate analysis, P < 0.01 were defined as statistically significant. The Kaplan-Meier method was used to determine survival time from the start of sorafenib treatment. To compare two variables, Receiver Operating Characteristic (ROC) analysis was used and cutoff values were decided by the Youden index. Qualitative variables were compared by diagnostic accuracy, which was calculated as (true positives + true negatives)/total number of samples.
Results

Patients characteristics
Of the 267 patients, 129 were excluded because of Child-Pugh class C, ECOG-PS values >2 or sorafenib discontinuation due to non-progressive disease (Fig. 1) . The number of patients who discontinued treatment due to adverse events was 79 (30%). Causes for sorafenib discontinuation were as follows: loss of appetite 22 (8%), liver failure 14 (5%), hand-foot-skin syndrome 10 (4%), fatigue 7 (3%), diarrhea 4 (1%) and thrombocytopenia 3 (1%). Sorafenib dosages were modified for 62 (23%) patients due to adverse effects. Early sorafenib discontinuation (<2 months) was seen in 71/267 (27%) patients. Thus, 138 patients with progressive disease after sorafenib therapy were analyzed. The clinical features of these patients are shown in Table 1 . The median administration period for sorafenib was 135 (13-1355) days, the sorafenib maintenance dose median was 400 (200-800) mg, and median dose intensity which was total dosage divided by duration was 400 (208-800) mg/day.
The clinical features of the regorafenib candidate and non-candidate groups
The regorafenib candidate group and the regorafenib non-candidate group comprised 61 and 77 patients, respectively.
The clinical features of these two groups are detailed in Table 2 . Age, sex, viral etiology and hepatic reserve function were compared between the two groups.
The median overall survival was 15.6 (95% CI: 10.5-21.7) months in the regorafenib candidate group and 6.8 (95% CI: 5.4-11.2) months in the regorafenib non-candidate group (P = 0.008). The 1-and 2-year survival rates were 55 and 23%, respectively, in the regorafenib candidate group and 36 and 16%, respectively, in the regorafenib non-candidate group (Fig. 2) .
Univariate analysis revealed that etiology (odds ratio: 0.300, 95% CI: 0.119-0.754, P = 0.011), AST ≥40 IU/l (odds ratio: 0.365, 95% CI: 0.168-0.777, P = 0.005), albumin ≥3.5 g/dl (odds ratio: 7.796, 95% CI: 3.032-22.910, P < 0.001), prothrombin time >85% (odds ratio: 2.503, 95% CI: 1.196-5.326, P = 0.010) and ALBI score <−2.53 (odds ratio: 10.496, 95% CI: 4.541-25.648, P < 0.001) were significant predictors at the start of regorafenib therapy.
Pearson correlation analysis showed that albumin levels and ALBI scores were significantly correlated (r = −0.96, P < 0.001). On the other hand, PT and ALBI scores were not as strongly correlated (r = −0.43, P < 0.001). Thus, albumin was not assessed in order to exclude it as a confounding factor in multivariable analysis. Multivariable analysis showed that only ALBI score <−2.53 as a significant predictor (odds ratio: 8.800, 95% CI: 3.750-20.700, P < 0.001) ( Table 3) . On the other hand, in intentto-treat analysis, the multivariate analysis result was the same (ALBI score <−2.53: odds ratio 5.580, 95% CI: 2.83-11.00, P < 0.001) (Supplementary Table 1) . We limited the analysis to only Child-Pugh class A and PS value = 0 or 1 patients and the results were not different (Supplementary Table 2 ). Thus, the ALBI score at the start of sorafenib treatment is useful for identifying candidate patients for regorafenib therapy.
The relationship between ALBI score and regorafenib prescribing criteria There was no difference in ALBI score between sorafenib tolerating patients (sorafenib dose ≥400 mg daily for at least 20 days) and non-tolerating patients (P = 0.20). Thus, it is likely that ALBI score at the time of diagnosis is predictive of Child-Pugh class A liver function in sorafenib-treated cases of progressive disease. We therefore compared Child-Pugh score and ALBI score at the start of sorafenib treatment. Area under the receiver operating curve (AUROC) analysis showed that ALBI score was not inferior to Child-Pugh score at the start of sorafenib treatment (AUROC: 0.78 and 0.72, P = 0.14). From ROC analysis, the ALBI score cutoff value was −2.53 (specificity: 0.792, sensitivity: 0.738). The diagnostic accuracy of ALBI score <−2.53 was 0.77 (95% CI: 0.69-0.84), and Child-Pugh score 5, 6 and >6 were 0.69 (95% CI: 0.60-0.76), 0.44 (95% CI: 0.36-0.53) and 0.43 (95% CI: 0.34-0.52), respectively. The diagnostic accuracy of albumin ≥3.5 g/dl was 0.67 (95% CI: 0.59-0.74). The difference between baseline ALBI score and postsorafenib ALBI score ALBI score significantly increased from baseline values to postsorafenib treatment measurements (baseline mean: −2.4, postsorafenib mean: −2.0, P < 0.01) (Fig. 3) . Furthermore, ALBI scores increased more in regorafenib non-candidate patients than in regorafenib candidate patients (P < 0.01, Fig. 4 ).
Discussion
In this multicenter study, the proportion who could switch from sorafenib to regorafenib among Child-Pugh class A and PS < 2 patients were 32.6%, a number similar to that found in previous reports (11) . The overall survival duration for the regorafenib candidate group was significantly better than for the regorafenib noncandidate group. Furthermore, the ALBI score at the start of sorafenib therapy was the only useful biomarker for the identification of regorafenib candidate patients. The patients who met the key inclusion criteria of the RESORCE trial demonstrated better outcomes than those who did not, and therefore we tried to identify the factors contributing to allow patients to meet these criteria.
In the RESORCE trial, the overall survival rate was significantly longer in the regorafenib group than in the placebo group. Thus, the expectation was that sorafenib-regorafenib sequential therapy could extend their prognosis. The overall survival period with sequential therapy was reported to be 26.1 months (13) . In the present study, the overall survival of the regorafenib candidate group was significantly better than that of the regorafenib non-candidate group even when they were not treated with regorafenib.
In the present study, the most common reason for sorafenib discontinuation was progressive disease. The second most common reason was liver dysfunction. Thus, it is very important to screen sorafenib-failure patients for preserved Child-Pugh class A status. Although patients treated with sorafenib and regorafenib sequential therapy are expected to have better outcomes, liver function gradually deteriorated during sorafenib treatment. In the present study, the average ALBI score increased about 0.39 points with sorafenib treatment. Thus, it is important to maintain hepatic function starting from when patients commence sorafenib therapy.
The Child-Pugh classification is the most commonly used system to evaluate liver function. It is composed of the following parameters: ascites, encephalopathy, albumin, bilirubin and prothrombin time. However, ascites and encephalopathy are more subjective than the other three factors. The ALBI score is composed of only albumin and bilirubin parameters and is therefore simpler and more objective than the Child-Pugh classification system. ALBI score accuracy is reported to be not inferior to Child-Pugh classification accuracy with respect to the 90-day mortality rate of post-sorafenib patients (areas under the ROC curve 0.69 and 0.66, respectively) (14) . In this study, the ALBI score was not inferior to the Child-Pugh score for the identification of candidate patients for regorafenib therapy.
Other retrospective studies have already reported concerning factors making it difficult to start regorafenib therapy in a patient (15,16). These factors include Child-Pugh score 6, albumin <3.5 g/dl, high AST levels and macrovascular invasion. In our study, univariate analysis accordingly indicated that AST <40 IU/l and albumin ≥3.5 g/dl were predictors for starting regorafenib therapy. According to the results of this study, the diagnostic accuracy of low ALBI scores at the start of sorafenib therapy was superior to that of low AST levels but not to macrovascular invasion and Child-Pugh score 6. Therefore, the diagnostic accuracy of the ALBI score <−2.53 metric was not inferior to that of the albumin ≥3.5 g/dl metric. The present study shows that low ALBI scoring patients at the point of sorafenib treatment start were likely candidates for regorafenib therapy. In other words, ALBI score can be used to predict which patients can receive sequential sorafenib-regorafenib therapy. Patients with low ALBI scores can be switched from sorafenib to regorafenib. This study has several limitations. First, it was not a large-scale study and was performed retrospectively. A prospective validation trial is needed. Second, patients were not administered regorafenib. Whether the ALBI score is a useful biomarker still needs to be confirmed in real-world clinical practice.
In conclusion, the ALBI score at the start point of sorafenib therapy is a useful biomarker for screening patient eligibility for sequential sorafenib-regorafenib therapy.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online. Figure 3 . ALBI score changes from baseline to sorafenib treatment endpoint. ALBI score increased significantly from the start of sorafenib therapy (−2.42) to the endpoint of sorafenib treatment (−2.02) (P < 0.01). Figure 4 . Comparison of ALBI score change between the regorafenib candidate and the regorafenib non-candidate groups. ALBI score increases were greater in regorafenib non-candidate group patients than regorafenib candidate group patients (P < 0.01).
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